Semaglutide and cardiovascular risk in type 1 diabetes: a predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial

Kugathasan, L.; Tsoukas, M.A.; Nardone, M.; Sridhar, V.S.; Muskiet, M.H.A.; Cherney, D.Z.I.; ... ; Pasqua, M. (2026)

Article / Letter to editor

• cardiovascular disease
• risk prediction
• semaglutide
• type 1 diabetes

• All authors: Kugathasan, L.; Tsoukas, M.A.; Nardone, M.; Sridhar, V.S.; Muskiet, M.H.A.; Cherney, D.Z.I.; Haidar, A.; Pasqua, M.
• Date: 2026-02-02
• Journal: Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics
• DOI: doi:10.1111/dom.70525